Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for <font color="red">advanced_1</font> <font color="red">nasopharyngeal_1</font> <font color="red">carcinoma_1</font> <font color="red">:_1</font> positive effect on <font color="red">overall_2</font> <font color="red">and_2</font> <font color="red">progression_2</font> <font color="red">-_2</font> <font color="red">free_2</font> <font color="red">survival_2</font> <font color="red">._2</font> <font color="red">
<br>
<br>_1</font> PURPOSE <font color="red">Nasopharyngeal_1</font> <font color="red">carcinoma_1</font> ( NPC ) is a radiosensitive and chemosensitive tumor . This randomized phase III trial <font color="red">compared_1</font> concurrent chemoradiotherapy ( CCRT ) versus radiotherapy ( RT ) alone in patients with advanced NPC . 
<br> PATIENTS AND METHODS From December 1993 to April 1999 , 284 patients with 1992 American Joint Committee on Cancer stage III to IV ( M0 ) NPC were randomly allocated into two arms . Similar dosage and fractionation of RT was administered in both arms . The investigational arm received two cycles of concurrent chemotherapy with cisplatin 20 mg / m(2)/d plus fluorouracil 400 mg / m(2)/d by 96-hour continuous infusion during the weeks 1 and 5 of RT . <font color="red">Survival_4</font> <font color="red">analysis_4</font> <font color="red">was_1</font> <font color="red">estimated_1</font> <font color="red">by_1</font> <font color="red">the_1</font> <font color="red">Kaplan_1</font> <font color="red">-_1</font> <font color="red">Meier_1</font> <font color="red">method_1</font> <font color="red">and_1</font> <font color="red">compared_1</font> <font color="red">by_1</font> <font color="red">the_1</font> <font color="red">log_1</font> <font color="red">-_1</font> <font color="red">rank_1</font> <font color="red">test_1</font> <font color="red">._1</font> <font color="red">
<br>_1</font> RESULTS <font color="red">Baseline_1</font> <font color="red">patient_1</font> <font color="red">characteristics_1</font> were comparable in both arms . After a median follow - up of 65 months , 26.2% ( 37 of 141 ) and 46.2% ( 66 of 143 ) of patients developed <font color="red">tumor_1</font> <font color="red">relapse_1</font> in the CCRT and RT - alone groups , respectively . <font color="red">The_1</font> <font color="red">5-year_2</font> <font color="red">overall_4</font> <font color="red">survival_4</font> <font color="red">rates_3</font> were 72.3% for the CCRT arm and 54.2% for the RT - only arm ( P = .0022 ) . <font color="red">The_1</font> <font color="red">5-year_2</font> <font color="red">progression_4</font> <font color="red">-_4</font> <font color="red">free_4</font> <font color="red">survival_4</font> <font color="red">rates_3</font> were 71.6% for the CCRT group compared with 53.0% for the RT - only group ( P = .0012 ) . Although <font color="red">significantly_2</font> <font color="red">more_2</font> <font color="red">toxicity_4</font> <font color="red">was_1</font> <font color="red">noted_1</font> in the CCRT arm , including <font color="red">leukopenia_2</font> <font color="red">and_2</font> <font color="red">emesis_2</font> <font color="red">,_2</font> <font color="red">compliance_1</font> with the combined treatment was good . The second cycle of concurrent chemotherapy was refused by nine patients and was delayed for > or = 1 week for another nine patients . There were <font color="red">no_3</font> <font color="red">treatment_2</font> <font color="red">-_2</font> <font color="red">related_2</font> <font color="red">deaths_3</font> in either arm . 
<br> CONCLUSION We conclude that <font color="red">CCRT_1</font> <font color="red">is_1</font> <font color="red">superior_2</font> <font color="red">to_1</font> <font color="red">RT_1</font> alone for patients with advanced NPC in endemic areas .